These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32081986)

  • 1. Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism.
    Vetma V; Guttà C; Peters N; Praetorius C; Hutt M; Seifert O; Meier F; Kontermann R; Kulms D; Rehm M
    Cell Death Differ; 2020 Aug; 27(8):2417-2432. PubMed ID: 32081986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism.
    Lincoln FA; Imig D; Boccellato C; Juric V; Noonan J; Kontermann RE; Allgöwer F; Murphy BM; Rehm M
    Cell Death Dis; 2018 Nov; 9(11):1112. PubMed ID: 30385739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines.
    Park EJ; Kim HD; Choi EK; Hoe KL; Kim DU
    Biochem Biophys Res Commun; 2020 Dec; 533(3):289-295. PubMed ID: 32958259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.
    Crawford N; Salvucci M; Hellwig CT; Lincoln FA; Mooney RE; O'Connor CL; Prehn JH; Longley DB; Rehm M
    Cell Death Differ; 2018 Nov; 25(11):1952-1966. PubMed ID: 29500433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
    Boccellato C; Kolbe E; Peters N; Juric V; Fullstone G; Verreault M; Idbaih A; Lamfers MLM; Murphy BM; Rehm M
    Cell Death Dis; 2021 Jun; 12(7):647. PubMed ID: 34168123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
    Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
    Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The X-linked inhibitor of apoptosis protein (XIAP) is involved in melanoma invasion by regulating cell migration and survival.
    Ayachi O; Barlin M; Broxtermann PN; Kashkar H; Mauch C; Zigrino P
    Cell Oncol (Dordr); 2019 Jun; 42(3):319-329. PubMed ID: 30778852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
    Vetma V; Rožanc J; Charles EM; Hellwig CT; Alexopoulos LG; Rehm M
    Oncol Res; 2017 Nov; 25(9):1489-1494. PubMed ID: 28337955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.
    An Y; Jeon J; Sun L; Derakhshan A; Chen J; Carlson S; Cheng H; Silvin C; Yang X; Van Waes C; Chen Z
    Sci Rep; 2021 Mar; 11(1):6392. PubMed ID: 33737574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.
    Passante E; Würstle ML; Hellwig CT; Leverkus M; Rehm M
    Cell Death Differ; 2013 Nov; 20(11):1521-31. PubMed ID: 23933815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoprotective effects of IAPs revealed by a small molecule antagonist.
    Galbán S; Hwang C; Rumble JM; Oetjen KA; Wright CW; Boudreault A; Durkin J; Gillard JW; Jaquith JB; Morris SJ; Duckett CS
    Biochem J; 2009 Feb; 417(3):765-71. PubMed ID: 18851715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative--Enhancement of both extrinsic and intrinsic apoptosis pathways.
    Berger A; Quast SA; Plötz M; Hein M; Kunz M; Langer P; Eberle J
    Biochem Pharmacol; 2011 Jan; 81(1):71-81. PubMed ID: 20858462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.
    Griffith TS; Kucaba TA; O'Donnell MA; Burns J; Benetatos C; McKinlay MA; Condon S; Chunduru S
    Apoptosis; 2011 Jan; 16(1):13-26. PubMed ID: 20734142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.